Hyderabad, Sep 11: Dr Reddy’s Laboratories Limited on Wednesday announced the launch of therapeutic generic equivalent of Emend (fosaprepitant) for injection, approved by the US Food and Drug Administration (USFDA).
“We are pleased to be among the first generics to launch this product,” explained Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories.
“This is a great addition to our injectable portfolio in the US market as we continue to augment our product offering and drive growth for the hospital segment,” he said.
The Emend for Injection brand had US sales of approximately USD 279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health, a company statement here said.
Dr Reddy’s Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution. (UNI)